glp 1 agonist history Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Oral Small-Molecule GLP-1 Receptor Agonists:
Description
Global Nonalcoholic Steatohepatitis Council
Secondary analysis of renal end points in a cardiovascular safety trial of a DPP-4 inhibitor in patients with T2DM at high cardiovascular risk, showing that saxagliptin reduces albuminuria in a glucose-independent manner
Nonetheless, the effect of GLP-1 RAs on HR should not be overlooked, because studies have shown that an elevated HR was potentially associated with a higher cardiovascular risk [353637]
For example, medications like ACE inhibitors , ARBs , and beta-blockers generally do not interfere with the cardiovascular benefits of GLP-1 therapies
